GEMIN6 Overexpression Correlates with the Low Immune Cell Infiltration and Poor Prognosis in Lung Adenocarcinoma

Table 1

Clinical characteristics of the enrolled LUAD cases from the TCGA database.

Characteristic	Levels	Overall
		535
T stage, (%)	T1	175 (32.9%)
	T2	289 (54.3%)
	T3	49 (9.2%)
	T4	19 (3.6%)
N stage, (%)	N0	348 (67.1%)
	N1	95 (18.3%)
	N2	74 (14.3%)
	N3	2 (0.4%)
M stage, (%)	M0	361 (93.5%)
	M1	25 (6.5%)
Pathologic stage, (%)	Stage I	294 (55.8%)
	Stage II	123 (23.3%)
	Stage III	84 (15.9%)
	Stage IV	26 (4.9%)
Gender, (%)	Female	286 (53.5%)
	Male	249 (46.5%)
Race, (%)	Asian	7 (1.5%)
	Black or African American	55 (11.8%)
	White	406 (86.8%)
Age, (%)	≤65	255 (49.4%)
	>65	261 (50.6%)
Smoker, (%)	No	75 (14.4%)
	Yes	446 (85.6%)
Number pack years smoked, (%)	<40	188 (50.9%)
	≥40	181 (49.1%)
GEMIN6 expression	Low	267 (49.9%)
	High	268 (50.1%)